Cancer Registry Report
The Cancer Registry is known for its substantial supportive role in the Missouri Baptist Medical Center’s Cancer Program. The Registry works with physicians, administrators, healthcare providers and planners to provide support for cancer program development, to ensure compliance to regulatory reporting requirements and standards, and to serve as a primary resource for cancer information and statistical information. A major function of the Registry is to record and analyze relevant patient data to include cancer diagnosis and treatment. The Registry also ensures compliance with the Commission on Cancer (CoC) standards, which ensures that Missouri Baptist provides the most comprehensive and patient centered cancer care for our patients.
The registry currently has almost 30,000 cancer patients entered into the database, representing individuals who were diagnosed and treated at Missouri Baptist Medical Center since its reference date in 2002. The Registry provides lifetime follow up on all of these patients. The information collected in follow up ensures continuous medical surveillance of the patient and enables monitoring of treatment efficacy and survival.
In addition to the primary functions of data collection relevant to each cancer patient we treat, the Registry is involved in analyzing cancer data for the purpose of education, research, quality of care and outcomes measurement. This data is submitted to the state and the National Cancer Database. Aggregate data can be used as a clinical surveillance mechanism in review of patterns of care, and outcomes and survival, with the ultimate goals being cancer prevention and quality treatment delivery.
Physicians and other healthcare professionals are encouraged to utilize the data collected by the Cancer Registry.
Analysis of Cancer Cases 2017
| Primary Site |
Total |
M |
F |
Analytic* |
Non-Analytic** |
| ORAL CAVITY & PHARYNX |
21 |
18 |
3 |
19 |
2 |
| Tongue |
4 |
4 |
0 |
4 |
0 |
| Salivary Glands, Major |
1 |
1 |
0 |
1 |
0 |
| Mouth, Other & Nos |
4 |
2 |
2 |
3 |
1 |
| Tonsil |
9 |
9 |
0 |
8 |
1 |
| Oropharynx |
2 |
1 |
1 |
2 |
0 |
| Hypopharynx |
1 |
1 |
0 |
1 |
0 |
| DIGESTIVE SYSTEM |
433 |
218 |
215 |
359 |
74 |
| Esophagus |
35 |
25 |
10 |
18 |
17 |
| Stomach |
39 |
16 |
23 |
30 |
9 |
| Small Intestine |
15 |
8 |
7 |
14 |
1 |
| Colon |
122 |
59 |
63 |
110 |
12 |
| Rectum & Rectosigmoid |
33 |
20 |
13 |
21 |
12 |
| Anus, Anal Canal, Anorectum |
12 |
4 |
8 |
9 |
3 |
| Liver |
25 |
18 |
7 |
21 |
4 |
| Gallbladder |
6 |
2 |
4 |
4 |
2 |
| Bile Ducts |
16 |
3 |
13 |
14 |
2 |
| Pancreas |
122 |
61 |
61 |
112 |
10 |
| Retroperitoneum |
3 |
1 |
2 |
3 |
0 |
| Peritoneum, Omentum, Mesentery |
3 |
0 |
3 |
2 |
1 |
| Other Digestive |
2 |
1 |
1 |
1 |
1 |
| RESPIRATORY SYSTEMS |
315 |
150 |
165 |
283 |
32 |
| Nose, Nasal Cavity & Middle Ear |
2 |
0 |
2 |
2 |
0 |
| Larynx |
3 |
2 |
1 |
3 |
0 |
| Lung/Bronchus-Small Cell |
55 |
28 |
27 |
48 |
7 |
| Lung/Bronchus-Non Sm Cell |
252 |
117 |
135 |
227 |
25 |
| Pleura |
1 |
1 |
0 |
1 |
0 |
| Other Respir & Thoracic |
2 |
2 |
0 |
2 |
0 |
| LEUKEMIA |
55 |
27 |
28 |
50 |
5 |
| MYELOMA |
29 |
14 |
15 |
24 |
5 |
| OTHER HEMATOPOETIC |
42 |
21 |
21 |
37 |
5 |
| BONE |
2 |
2 |
0 |
1 |
1 |
| SOFT TISSUE |
4 |
2 |
2 |
2 |
2 |
| SKIN |
26 |
18 |
8 |
17 |
9 |
| Melanoma of Skin |
23 |
15 |
8 |
15 |
8 |
| Other Skin Cancer |
3 |
3 |
0 |
2 |
1 |
| EYE |
1 |
1 |
0 |
1 |
0 |
| Melanoma of Uvea |
1 |
1 |
0 |
1 |
0 |
| BREAST |
356 |
2 |
354 |
325 |
31 |
| FEMALE GENITAL SYSTEM |
193 |
0 |
193 |
157 |
36 |
| Cervix Uteri |
27 |
0 |
27 |
21 |
6 |
| Corpus Uteri |
110 |
0 |
110 |
98 |
12 |
| Uterus Nos |
4 |
0 |
4 |
3 |
1 |
| Ovary |
26 |
0 |
26 |
22 |
4 |
| Vagina |
1 |
0 |
1 |
1 |
0 |
| Vulva |
22 |
0 |
22 |
9 |
13 |
| Other Female Genital |
3 |
0 |
3 |
3 |
0 |
| MALE GENITAL SYSTEM |
133 |
133 |
0 |
98 |
35 |
| Prostate |
120 |
120 |
0 |
86 |
34 |
| Testis |
12 |
12 |
0 |
12 |
0 |
| Other Male Genital |
1 |
1 |
0 |
0 |
1 |
| URINARY SYSTEM |
167 |
110 |
57 |
156 |
11 |
| Bladder |
70 |
52 |
18 |
63 |
7 |
| Kidney & Renal Pelvis |
87 |
54 |
33 |
84 |
3 |
| Ureter |
7 |
2 |
5 |
7 |
0 |
| Other Urinary |
3 |
2 |
1 |
2 |
1 |
| BRAIN & OTHER NERVOUS SYSTEM |
36 |
16 |
20 |
33 |
3 |
| Brain |
14 |
10 |
4 |
12 |
2 |
| Other Nervous System |
22 |
6 |
16 |
21 |
1 |
| ENDOCRINE SYSTEM |
50 |
10 |
40 |
45 |
5 |
| Thyroid |
44 |
6 |
38 |
41 |
3 |
| Other Endocrine |
6 |
4 |
2 |
4 |
2 |
| LYMPHOMA |
60 |
39 |
21 |
53 |
7 |
| Hodgkin's Disease |
9 |
5 |
4 |
8 |
1 |
| Non-Hodgkin's Lymphoma |
51 |
34 |
17 |
45 |
6 |
| UNKNOWN OR ILL-DEFINED |
16 |
7 |
9 |
14 |
2 |
| Total |
1939 |
788 |
1151 |
1674 |
265 |
*Analytic cases: Diagnosed and/or treated first course treatment at Missouri Baptist
**Non-analytic cases: Received subsequent treatment at Missouri Baptist (diagnosed and all first-course treatment received elsewhere).
Top Cancer Sites
| Site |
Missouri Baptist |
State of Missouri |
| |
Total |
Percentage |
Total |
Percentage |
| Breast |
356 |
18% |
4930 |
14% |
| Lung |
307 |
16% |
5620 |
16% |
| Colorectal |
155 |
8% |
2860 |
8% |
| Pancreas |
122 |
6% |
1070 |
3% |
| Prostate |
120 |
6% |
2990 |
9% |
Skin Cancer Screening at Missouri Baptist Medical Center
Skin cancer is the most common type of cancer in the United States, most can be treated successfully if detected early. Lee Portnoff, MD, leads the St. Louis region's annual St. Louis Dermatological Society Skin Cancer Screening Program. Missouri Baptist participates as one of several sites including: Barnes-Jewish West County Hospital, Barnes-Jewish St. Peters Hospital, Mercy Hospital St. Louis, SSM St. Clare Hospital, St. Anthony's Medical Center, St. Louis University School of Medicine, and St. Luke's Hospital.
In support of this effort, Rebecca Peck, MD; Osamuede Osemwota, MD; and Dr Portnoff participated in a screening event at Missouri Baptist Medical Center on May 19, 2018.
Forty-three (43) people were screened at this one day event and 2 basal cell cancers were identified. An additional 7 patients were recommended for biopsy. Patients were given a form to identify the location of suspicious area and advised to follow up with their dermatologist. Patients without a dermatologist were provided a list from the St. Louis Dermatological Society.